CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Long-Term, Open-Label Extension Study of Guanfacine Extended Release in Children and Adolescents with ADHD

Biederman, Joseph, Melmed, Raun D., Patel, Anil, McBurnett, Keith, Donahue, Jessica, Lyne, Andrew · 2008 · CNS Spectrums

Abstract

Introduction: Guanfacine is a noradrenergic agonist that is believed to improve symptoms of attention-deficit/hyperactivity disorder (ADHD) through selective actions at α 2A-adrenoceptors in the prefrontal cortex. A recent double-blind, multicenter trial supports the efficacy and safety of guanfacine extended release (GXR) for pediatric ADHD. This long-term, open-label extension was conducted to study the safety profile and effectiveness of GXR for up to 2 years. Methods: Subjects were 240 children 6–17 years of age with a diagnosis of ADHD who participated in the preceding randomized trial. GXR was initiated at 2 mg/day and titrated as needed in 1-mg increments to a maximum of 4 mg/day to achieve optimal clinical response. Results: The most common adverse events were somnolence (30.4%), headache (26.3%), fatigue (14.2%), and sedation (13.3%). Somnolence, sedation, and fatigue were usually transient. Cardiovascular-related adverse events were uncommon, although small reductions in mean blood pressure and pulse rate were evident at monthly visits. ADHD Rating Scale, Version IV, total and subscale scores improved significantly from baseline to endpoint for all dose groups (P<.001 for all comparisons, intent-to-treat population). Conclusion: Long-term treatment with GXR was generally safe for up to 24 months of treatment, and effectiveness was maintained over this treatment period.

Overview

Integrity signals

Registry

Crossref · 10.1017/s1092852900017107

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. Sallee, J Am Acad Child Adolesc Psychiatry

Cited by

See all 273

Metadata

Authors
Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Donahue, J., & Lyne, A.
Affiliations
Massachusetts General Hospital (US)
Venue
CNS Spectrums
Published
2008-12
Volume
13
Issue
12
Pages
1047-1055
ISSN
  • 1092-8529 (ISSN-L)
  • 2165-6509
OpenAlex
W181776045
Cited by
270
References
24
Citations by year
2025: 3 · 2024: 7 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 162 · 2019: 6 · 2018: 5 · 2017: 1 · 2016: 4 · 2015: 7 · 2014: 14 · 2013: 10 · 2012: 14
FWCI
6.51
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Spectrums (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
guanfacine extended release, attention deficit hyperactivity disorder, children with ADHD, long-term treatment safety, efficacy, alpha2A-adrenoceptor, sleepiness, sedation, blood pressure reduction, ADHD Rating Scale-IV
MeSH terms
Adolescent, Adrenergic alpha-Agonists, Attention Deficit Disorder with Hyperactivity, Blood Pressure, Child, Dose-Response Relationship, Drug, Fatigue, Female, Headache, Humans, Disorders of Excessive Somnolence, Male, Time Factors, Guanfacine, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term, Open-Label Extension Study of Guanfacine Extended Release in Children and Adolescents with ADHD. https://app.cochat.ai/papers/10.1017/s1092852900017107
The paper
Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Donahue, J., & Lyne, A. (2008). Long-Term, Open-Label Extension Study of Guanfacine Extended Release in Children and Adolescents with ADHD. CNS Spectrums. https://doi.org/10.1017/s1092852900017107

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.